

ERRATUM

Open Access



# Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Antoine Adenis<sup>1,13\*</sup>, Christelle de la Fouchardiere<sup>2</sup>, Bernard Paule<sup>3</sup>, Pascal Burtin<sup>4</sup>, David Tougeron<sup>5</sup>, Jennifer Wallet<sup>6</sup>, Louis-Marie Dourthe<sup>7</sup>, Pierre-Luc Etienne<sup>8</sup>, Laurent Mineur<sup>9</sup>, Stéphanie Clisant<sup>10</sup>, Jean-Marc Phelip<sup>11</sup>, Andrew Kramar<sup>6</sup> and Thierry Andre<sup>12</sup>

## Erratum

After publication of the original article [1], an error was noticed within the title: acronym “REBECCA” was erroneously written as “REBACCA”. The original article has now been updated with the correct title which can also be found above. The publisher would like to apologise for this error and for any inconvenience this may have caused.

## Author details

<sup>1</sup>Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France. <sup>2</sup>Medical Oncology, Centre Léon Bérard, Lyon, France. <sup>3</sup>Medical Oncology, Paul Brousse University Hospital, Villejuif, France. <sup>4</sup>Medical Oncology, Gustave Roussy, Villejuif, France. <sup>5</sup>Gastroenterology, University Hospital, Poitiers, France. <sup>6</sup>Methodology and Biostatistics, Centre Oscar Lambret, Lille, France. <sup>7</sup>Medical Oncology, Clinique Sainte Anne, Strasbourg, France. <sup>8</sup>Medical Oncology, Hôpital Privé des Côtes d’Armor, Plérin, France. <sup>9</sup>Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France. <sup>10</sup>Clinical Research Unit, Centre Oscar Lambret, Lille, France. <sup>11</sup>Gastroenterology, University Hospital, Saint Etienne, France. <sup>12</sup>Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France. <sup>13</sup>Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000 Lille, France.

Received: 13 July 2016 Accepted: 13 July 2016  
Published online: 25 July 2016

\* Correspondence: a-adenis@o-lambret.fr

<sup>1</sup>Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France

<sup>13</sup>Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000 Lille, France

Full list of author information is available at the end of the article

## References

1. Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. *BMC Cancer*. 2016;16:412. doi:10.1186/s12885-016-2440-9.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

